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Patients with Systemic Lupus Erythematosus (SLE) are at increased risk for infections. Vaccination is a powerful tool
to prevent infections, even in immunocompromised patients. Most non-live vaccines are immunogenic and safe in
patients with SLE, even if antibody titres are frequently lower than those of healthy controls. Human papillomavirus
(HPV) infections are more prevalent in SLE patients when compared to the healthy population. Low-risk types of
this virus cause anogenital warts, while high risk types are strongly related to pre-malignant cervical abnormalities
and cervical cancer. HPV vaccines have been developed to prevent these conditions. Although little is known about
HPV vaccination in SLE, few studies in patients with autoimmune rheumatic diseases (AIRDs) have shown that HPV
vaccines are safe, and capable to induce an immunogenic response in this group of patients. To date, available
data suggest that HPV vaccines can be given safely to SLE patients. Given the increased incidence of cervical
abnormalities due to HPV in SLE patients, this vaccination should be encouraged.
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Systemic lupus erythematosus (SLE) is an immune dis-
order that predominantly affects women of reproductive
age. The disease is characterized by chronic inflamma-
tion, circulating autoantibodies, and heterogeneous mul-
tisystemic involvement. It is well known that SLE
patients are at increased risk for infections [1–7]. This
might be due to the dysregulation of their immune sys-
tem as well as the immunomodulatory therapy used by
these patients [2, 4, 7–10].
Vaccines present one of the most effective tools to pre-
vent infectious diseases. Ideally, vaccines should be im-
munogenic (i.e., capable to induce an antibody response),
effective (i.e., provide protection) and safe. Vaccine safety
in patients with chronic inflammatory conditions can be
broken down into two separate concerns. Firstly, there is a* Correspondence: N.Wulffraat@umcutrecht.nl
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disease. Secondly, in case of live-attenuated vaccines, there
is a possibility to induce overt infection [9, 11]. When con-
sidering vaccinating a SLE patient, these issues should be
addressed [2, 4, 8–11].
Protective immunity is dependent on a functional im-
mune system that induces both adequate antibody levels
as well as memory to achieve short term and long-term
protection [2, 8, 9, 11]. As SLE patients have a dysfunc-
tional immune system, there is a risk that their immune
response to vaccination could be impaired. However,
studies have demonstrated that most vaccines are effica-
cious in patients with SLE, even if specific immune re-
sponses may be reduced when compared to the responses
of the healthy population [4, 5, 11–13].
In this review, we aim to give an overview of the risks
of contracting oncogenic HPV infections in patients with
SLE. Additionally, we describe the importance and rele-
vance of the HPV vaccines in this group of patients.
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lent (qHPV), and most recently, 9-valent (9vHPV) vac-
cines [14–16]. These vaccines were developed to prevent
pre-malignant cervical lesions and cervical cancer. qHPV
and 9vHPV also prevent benign conditions caused by
HPV, like anogenital warts. All these conditions are
more common in patients with SLE when compared to
healthy population [17–27].
Vaccination in patients with Systemic Lupus
Erythematosus
The European League Against Rheumatism (EULAR)
has published general recommendations for the use of
vaccines in autoimmune rheumatic diseases (AIRDs)
[28, 29]. When indicated in national guidelines, non-live
vaccines can be administered independent of medication
use. It is recommended to withhold live-attenuated
vaccines in patients on high-dose disease modifying
anti-rheumatic drugs (DMARDs), high-dose glucocorti-
costeroids or biological agents. Boosters vaccinations
can be considered in patients receiving a low dose of im-
munosuppressive medications [28, 29].
Irrespective of the AIRD, the majority of immunosup-
pressive drugs do not seem to have a detrimental effect on
the immune response against vaccines, especially when
the drug is administered in low doses [28, 29]. There is
one important exception: rituximab, an anti CD-20 anti-
body. This drug acts through depletion of lymphocytes B
and therefore strongly impairs the humoral immune re-
sponse to vaccines. For this reason, it is recommended to
vaccinate before or at least six months after administra-
tion of this medication [11, 28, 29].
Pneumococcal polysaccharide vaccine (PPSV23) and in-
fluenza vaccines have been researched extensively in pa-
tients with SLE, as these pathogens are responsible for the
most common infections in patients with SLE [1, 4, 5].
Studies show that these two non-live composite vaccines
are safe in this patient population. Vaccinated patients
show hardly any change in disease activity. Patients did
have a lower specific immune response when compared to
the general population, but the majority of them produced
protective antibody levels. No clear effect of immunosup-
pressive drugs or biological agents on the antibody titres
was reported [1, 4, 5]. In pediatric patients, only influenza
vaccines have been studied, with similar results to the
adults trials [1, 11, 30–33].
The Hepatitis B Virus (HBV) vaccine, another non-live
composite vaccine, has been studied in this population
as well. One adult study with 28 patients and one
pediatric study with 64 patients had showed lower anti-
body seroconversion rates, but still adequate humoral
response against the virus in patients with SLE. There
were no significant exacerbation of disease, nor adverse
effects after HBV vaccination [1, 11–13].The most important concern regarding live-attenuated
vaccines in patients with SLE relates to the risk of devel-
oping overt infections of live-attenuated pathogens in the
vaccine [3]. Only two prospective studies using a live at-
tenuated virus vaccine in SLE patients have been
published. One studied the varicella-zoster virus (VZV)
vaccine in childhood-onset SLE patients who were previ-
ously immune to varicella virus. This study showed ad-
equate immunogenicity and safety [34]. The other also
studied the VZV-vaccine, in 10 SLE patients older than
50 years. The vaccine was safe: no episodes of herpes zos-
ter or vesicular rash, no serious adverse events or SLE
flares were reported [6].
Vaccination in immunocompromised patients can re-
duce the burden of infections [11, 28]. As these patients
have many benefits from effective vaccination strategies,
new vaccines should be assessed in this population as
well. The most recent example are vaccines against the
human papillomavirus (HPV), that have been studied in
healthy and immunocompromised individuals in the last
years, with satisfactory results.
Human Papillomavirus infections and vaccination
in the healthy population
HPV infection is the most common sexually transmitted
disease (STD) in the world [35–39]. The virus is able to
infect the skin, mucous membranes of the anogenital re-
gion, as well as conjunctiva, oral and nasal mucosas, lar-
ynx and pharynx [37, 40]. Depending on the subtype, the
virus can cause pre-malignant cervical abnormalities and
cervical cancer as well as benign conditions such as ano-
genital warts. Besides sexual transmission, there are stud-
ies reporting transplacental and perinatal transmission
[41–43]. It seems that the transmission is significantly
lower when caesarean section is performed. In the major-
ity of cases, the viral DNA does not persist in the newborn
for more than 6 months [41–45]. Recurrent laryngeal
papillomatosis, which is the most important clinical con-
sequence of infantile HPV 6 and 11 infections, is a rare
consequence of HPV chronicity in the newborn [44, 45].
The prevalence of HPV infection varies according to
gender, age, population and geographic region. A large
systematic review about HPV prevalence in women
encompassed data from 70 countries worldwide [46].
Age is the strongest predictor, as the highest HPV preva-
lence in all studies around the world is found in women
between 16 and 24 years old [35–37, 39, 46]. The review
showed an age-stratified HPV prevalence that varied
considerably across geographical regions and study
population, ranging from less than 2 % to approximately
70 %, even in the same continent. Women under 25 were
the most affected group in all study populations. Some re-
gions, especially in America and Africa, showed a second
peak among women older than 45 years old [46].
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which covers over 120 genotypes classified according to
the organization of DNA sequences and their oncogenic
potential. About 40 of them are able to infect the human
anogenital tract [35–38]. The most important types are
showed in Table 1. The low risk subtypes are responsible
for benign abnormalities such as anogenital warts. The
subtypes 16 and 18 are responsible for 70 % of all cer-
vical cancers, around 50 % of high-grade intraepithelial
lesions (HSIL) and 30–50 % of low-grade intraepithelial
lesions (LSIL). Together with the other high risk sub-
types, they encompass 99.7 % of all cervical dysplasias,
pre-malignant abnormalities, and cervical cancers
[35–38]. A system for reporting these cervical cyto-
logic diagnoses is the Bethesda System, created in
1988 and last updated in 2014 (Table 2) [47, 48].
Cancers caused by HPV include all cancers of the cer-
vix, most anal (88 %) and vaginal (70 %) cancers, and
part of vulvar (43 %), penile (50 %), and oropharyngeal
cancers (26 %) [40]. The most recent estimate of the
worldwide incidence and mortality of 27 major types of
cancer, ranked cervical cancer as the fourth most com-
mon cancer in women. Interestingly, 84 % of the cases
as well as 87 % of the deaths due to cervical cancer oc-
curred in the more poorly developed regions [40, 49].
This is a consequence of more effective programs of
population screening in developed countries, which pro-
vide early diagnosis and treatment and a higher chance of
curing this cancer [40]. In the absence of screening pro-
grammes as in poorer countries is often the case, simple
vaccination strategies could thus be extra effective.
HPV infection alone is not sufficient to develop cer-
vical abnormalities. The combination of the virus’ onco-
genicity, its persistence in the infected tissue and the
response of the host immune system determine the evo-
lution of the infection [35–38, 40, 50]. In a large number
of cases, the immune system is capable of clearing the
virus in 1 to 5 years, without any treatment. Thus, only
a minority of individuals infected with HPV develop
clinical complications (Fig. 1). Women who are younger
at first sexual intercourse or who have multiple sexual
partners have a higher risk to develop HPV abnormal-
ities, since they are more likely to be exposed to
oncogenic subtypes as well as to a high charge of the
virus. Smoking and hormonal contraception can causeTable 1 Classification of HPV genotypes by cervical
oncogenicity
Oncogenic potential HPV genotypes
Low risk 6, 11, 40, 42, 43, 44, 54, 61, 72, 81, 89
High risk 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59
Probably/Possible high risk 26, 53, 66, 68, 73, 82
Abbreviations: HPV human papillomavirus
Adapted from Erickson et al. [37]immunological dysregulations that facilitate the genetic
expression of HPV. The presence of other STDs in-
creases the risk of disease development as well. In
addition, immunosuppression or immunodeficiency can
facilitate viral persistence in the host [35–38, 40, 50].
As the evolution of HPV infection to pre-malignant
cervical abnormalities and cervical cancer takes decades
in health women, it is possible to identify pre-malignant
lesions by conducting screening tests. Conventional cy-
tology tests (Papanicolaou test or Pap test) are the most
widespread method used in cervical cancer screening.
The test should be performed at each 3-year interval
[16, 50–52]. In the past years, HPV DNA tests have been
incorporated by developed countries for the screening of
HPV infections. These tests have a higher sensitivity and
are slightly less specific when compared with Pap test.
The new guidelines suggest that the cervical screening
of women 30 and over can be extended to 5-year inter-
val when negative Pap test is combined with HPV DNA
test [16, 50–52]. For women younger than 30 years,
HPV DNA testing alone or in combination with Pap test
are not recommended due to the high prevalence of
HPV infection at this age, as well as the rarity of pro-
gression of those infections to invasive cancer [52].
Evidence from current studies suggests that the peri-
odic tests should be complemented with HPV vaccin-
ation, aiming at primary prevention of infection with the
virus [16, 40, 51]. Currently, three types of prophylactic
HPV vaccines are available. The bHPV vaccine is di-
rected against two high-risk genotypes, 16 and 18. The
qHPV vaccine is also directed against these two high-
risk HPV genotypes, but also provides protection against
the low risk genotypes 6 and 11. Clinical data shows that
both vaccines are safe and generate adequate antibody
levels up to 4.5 years after vaccination [53–56]. A 9-
valent HPV vaccine was licensed in December 2014 by
the Food and Drug Administration (FDA), and in March
2015 by the European Medicine Agency. This vaccine
offers protection against an additional five HPV high-
risk genotypes. This should increase prevention of cer-
vical cancer from 70 to 90 %, as well as prevent 85–95 %
of HPV-related vulvar, vaginal and anal cancers. As this
vaccine has just been approved, no clinical effectiveness
data is yet available [14, 15, 57, 58].
The HPV vaccines have been incorporated in National
Immunization Programs (NIP) across the globe, targeting
9 to 13 years old girls, with an original three dose regimen
[40, 59]. Recently, the World Health Organization (WHO)
updated its HPV vaccines position paper to recommend a
two dose regimen with a 6-month interval between doses
for immunocompetent girls younger than 15 years at the
time of the first dose [59]. Different from European coun-
tries, The United States, Canada and Australia have incor-
pored HPV vaccination for boys from 9 to 12 years old in
Table 2 Bethesda System (Last update in 2014)
Terminology Interpretation
Negative for intraepithelial lesion or malignancy No cellular evidence of neoplasia
Squamous cells:
Atypical squamous cells:
Of undetermined significance (ASC-US) Undetermined
Cannot exclude HSIL (ASH-H) Cannot exclude pre-malignant lesion
Low-grade squamous intraepithelial lesion (LSIL) HPV/mild dysplasia/CIN-1
High-grade squamous intraepithelial lesion (HSIL) Moderate and severe dysplasia/CIN-2 and CIN-3/SIC
Squamous cell carcinoma Invasive cancer
Glandular cells:
Atypical glandular cells Undetermined or cannot exclude pre-malignant lesion
Endocervical adenocarcinoma is situ CIS
Adenocarcinoma Invasive cancer
Abbreviations: CIN cervical intraepithelial neoplasia, CIS carcinoma in situ, HPV human papillomavirus
Adapted from Nayar and Wilbu [48]
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men younger than 21 years can also be benefited by the
HPV vaccination [14, 40, 59].
All three vaccines show high efficacy in prevention of
vaccine-specific HPV-type infection and associated high-
grade cervical dysplasia in HPV-naïve women (Table 3)
[57]. Despite bHPV and qHPV vaccines having been ap-
proved only 10 years ago, a meta-analysis of 20 studies
performed in developed countries has already showed
significant decrease of HPV prevalence in young vac-
cinated men and women [60]. Due to the lag-time
between HPV infection and the development of can-
cer, a decreased incidence of HPV-related cancers
can only be determined after several decades. In
order to reduce the incidence and mortality from
cervical cancer globally, these vaccines should have a
high coverage in the population [40]. Figure 2 shows
the most important events in the history regarding
the screening and prevention of HPV infection and
cervical cancer.Normal
HPV 
Infection
LS
Infection Progression
RegressionClearance
HSILNormal
A
B
Fig. 1 a Sequential steps for cervical cancer: Infection with carcinogenic HPV
progression of cervical premalignant lesion, and finally, invasion (Adapted from
squamous intraepithelial lesion (HSIL) and Squamous Cell CarcinomaHuman Papillomavirus infections and vaccination
in Systemic Lupus Erythematosus patients
Studies from all over the world showed that HPV infec-
tions are more prevalent in patients with SLE [17–27].
Santana et al. performed a systematic review of 33 stud-
ies. They concluded that the diagnosis of SLE directly in-
creases the risk of developing cevical dysplasias and pre-
malignant lesions [20]. Although the majority of the
studies showed that SLE patients had more pre-
malignant lesions than healthy women, the prevalence of
cervical cancer was similar between SLE patients and
healthy populations in almost all studies [20]. Only one
study included in the review found an increased preva-
lence of cervical cancer in SLE patients [20, 21]. The in-
creased risk of pre-malignant lesions in this population
was confirmed in a meta-analysis performed by Zard
et al. [23]. Seven studies about the prevalence of pre-
malignant cervical lesions in patients with SLE were
included. They showed a 9-fold increase risk on pre-
malignant cervical lesions in this population whenIL HSIL Cancer
Progression Invasion
Regression
Squamous Cell Carcinoma
type(s), followed by detectable viral persistence, linked to the
Schiffman M. et al.) [50]. b Colposcopy of normal cervix, high-grade
Table 3 HPV vaccines efficacy and cervical cancer coverage
Vaccine HPV genotypes Vaccine efficacy Cervical cancer coverage
bHPV 6 and 18 >98 % for HPV disease related to genotypes 6 and 18 70 %
qHPV 6, 11, 16 and 18 >99 % for HPV disease related to genotypes 6, 11, 16 and 18 (women)
90 % for external genital disease (men)
70 %
9vHPV 6, 11, 16 and 18
31, 33, 45, 52 and 58
>99 % for HPV disease related to genotypes 6, 11, 16 and 18
96,7 % for HPV disease related to genotypes 31, 33, 45, 52 and 58
90 %
Abbreviations: bHPV bivalent vaccine, qHPV quadrivalent vaccine, 9vHPV 9-valent vaccine, HPV human papillomavirus
Adapted from Committee Opinion number 641 [57]
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cluded in this meta-analysis did not include any long
term follow-up data. Whether these pre-malignant le-
sions progress to cervical cancer remains unclear. An ex-
planation for the higher prevalence of cervical dysplasia
in SLE patients is that clearance of HPV could be related
to adequate innate and adaptative immune responses. As
these are impaired in patients with SLE, clearance of the
virus could also be impaired or merely delayed, resulting
in persistent carriage of HPV, as well as persistent le-
sions [20, 23, 24, 61].
There is no consensus in the literature regarding the
role of immunosuppressive drugs as a predisposing factor
for the cervical abnormalities caused by HPV [19, 20, 25].
The majority of the studies showed no association. How-
ever, some evidence suggests azathioprine and intravenous
cyclophosphamide use could contribute to the develop-
ment of persistent HPV infections and subsequent com-
plications [19, 20, 25–27].
It is clear that patients with SLE are at increased risk
to develop HPV infections. Thus, it is reasonable that
more rigorous criteria should be applied to cervical can-
cer screening in SLE patients, with shorter intervals in
between examinations than the general population,1920
1980 1990 2
Harold zur Hausen
discovers HPV infection
linked to cervical cancer
Bethesda System
created
HPV DN
FDA ap
George Papanicolau
begins work on vaginal smears
Fig. 2 Important events regarding cervical cancer and HPV. Abbreviations:
vaccine; HPV, human papillomavirus; FDA, Food and Drug Administration. Aassociated to HPV vaccination [19]. The introduction of
the HPV vaccines presents an opportunity for cervical
cancer prevention. SLE patients should benefit from pre-
ventive vaccination. Therefore, it is essential that the
safety, immunogenicity and efficacy of the HPV vaccine
in this specific population will be studied.
The EULAR recommendations for both children and
adults with rheumatic diseases state that the HPV vac-
cine should be considered in patients with autoimmune
diseases. An association with venous thromboembolic
events (VTE) and the qHPV vaccine had been reported,
which led to a side note on this in the recommendations
regarding the vaccine [62]. However, current evidence
from 997.585 girls did not show any association between
HPV vaccination and possible VTE. In this large cohort,
no associations between HVP vaccination and auto-
immune or neurological adverse events could be shown
either [63].
Since the HPV vaccines were licensed, six original arti-
cles and one systematic review have been published re-
garding the safety and immunogenicity of these vaccines
in patients with autoimmune disease [53, 54, 64–67].
Three articles studied the safety and immunogenicity of
the vaccine in SLE patients [66–68], two in juvenile000 2010 2020
A testing
proved
bHPV FDA approved
qHPV FDA approved
9vHPV FDA approved
bHPV, bivalent vaccine; qHPV, quadrivalent vaccine; 9vHPV, 9-valent
dapted from Lees et al. [16]
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with juvenile dermatomyositis (JDM) [68] and one in pa-
tients with inflammatory bowel disease (IBD) [65]. Over-
all, the vaccine seems to be safe and immunogenic in
patients with an autoimmune disease.
The largest study assessing immunogenicity and safety
of the HPV vaccine in patients with SLE included 50 SLE
patients and 50 healthy controls between the age of 18
and 35 years. At twelve months after receiving the first
vaccination, seroconversion rates in both groups were ad-
equate (Patients vs Controls: HPV 6: 82 % vs 98 %,
HPV11: 89 % vs 98 %, HPV16: 95 % vs 98 %, HPV18: 98 %
vs 80 %). A lower immunogenicity of the vaccine was as-
sociated with the use of low-dose prednisolone or myco-
phenolate mofetil. Adverse events were not different
between patients and controls. No significant difference in
rate of flares in the vaccinated group and a control group
of unvaccinated SLE patients was found [66].
A pilot study included 6 patients with childhood-onset
SLE who were vaccinated in the context of the national
vaccination program [68]. The vaccine induced seroposi-
tivity for all isotypes in a high proportion of patients, al-
though the geometric mean titres were lower in patients
than those in healthy controls. An uncontrolled study in
20 SLE patients also showed a high seropositivity rate
for all isotypes [67]. In both studies, disease activity was
measured with the SLE Disease Activity Index (SLEDAI).
Prior to vaccination, disease activity was low in all pa-
tients. During follow-up, disease activity remained low.
Ten mild/moderate flares were reported. These flares
were generally similar to the flares the patients had in
the year prior to vaccination.
One study evaluated the change in hospitalizations for
SLE in the United States since the introduction of the
HPV vaccine, to assess its safety [70]. In this study, no evi-
dence of an increased amount of hospitalizations for SLE
was found since the introduction of the HPV vaccine.
The HPV vaccines have been studied in small groups of
patients with autoimmune diseases. In these groups, the
vaccines are shown to be immunogenic and safe. As anti-
body titres are a proxy for protection for most vaccines,
larger, controlled studies are needed to compare the anti-
body titres in patients and in controls. When antibody ti-
tres are low, an adequate immunologic memory could still
indicate that individuals are adequately protected when
they encounter the virus. Therefore, specific memory
against HPV also needs to be assessed in patients with
SLE. Additionally, long-term studies are necessary to as-
sess the effect of HPV vaccination on the prevalence of
persistent high-risk HPV infections in patients with SLE.
Conclusion
Infections represent the main cause of death in patients
with SLE. Vaccination is the most important tool in theprevention of infections, and for this reason it is an im-
portant topic to be discussed in order to improve the
care of SLE patients. Although some questions still re-
main, diverse studies have shown the immunogenicity
and safety of non-live vaccines in patients with SLE.
Therefore, use of these vaccines should be encouraged
by health professionals.
Evidence about the immunogenicity and safety of live-
attenuated vaccines in SLE patients is still scarce. More
studies are needed to elucidate the level of immunosup-
pression that turns out patients to be at risk from live
agents present in the vaccines, as well as the pattern of
immune system response and memory production after
vaccination.
HPV is essential in the pathophysiology of pre-
malignance cervical abnormalities and cervical cancer,
conditions that are highly prevalent among women in all
the world. Women with SLE present even higher risk of
development HPV diseases. SLE predominantly affects
women of reproductive age, that is the same group
where the occurrence of HPV infection is increased. As
the immune system of SLE patients is abnormal, the
clearance of the virus is impaired. The result is the per-
sistence of HPV virus in the cervix of SLE patients more
often than in healthy women, what leads to higher
prevalence of cervical dysplasia and cancer in SLE fe-
male population.
Non-live HPV vaccines are safe and able to produce a
protective response even in patients with autoimmune
diseases. These findings represent a great benefit for
public health. Especially in poorer countries with absent
screening programs, HPV vaccination strategies should
be implemented. Despites the vaccines have been ap-
proved only 10 years ago, studies performed in devel-
oped countries already showed significant decrease of
HPV prevalence in young vaccinated men and women
[40, 60]. Future studies will have to be performed to
evaluate the reduction in incidence of cervical cancer
and other HPV-related cancers after decades of HPV
vaccines implementation, as well as the HPV vaccines’
long term efficacy in patients with SLE.Abbreviations
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